REPLIGEN CORP Payments to Acquire Marketable Securities
REPLIGEN CORP (RGEN) reported Payments to Acquire Marketable Securities of $130.70 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-07-29
- REPLIGEN CORP payments to acquire marketable securities for the quarter ending 2026-06-30 was $66.07M.
- REPLIGEN CORP payments to acquire marketable securities for the quarter ending 2026-03-31 was $64.63M.
- REPLIGEN CORP payments to acquire marketable securities for the quarter ending 2025-06-30 was $0.00.
- REPLIGEN CORP payments to acquire marketable securities for the quarter ending 2025-03-31 was $0.00.
- REPLIGEN CORP payments to acquire marketable securities for fiscal 2025 was $200.26M.
- REPLIGEN CORP payments to acquire marketable securities for fiscal 2024 was $0.00.
- REPLIGEN CORP payments to acquire marketable securities for fiscal 2023 was $0.00.
- REPLIGEN CORP payments to acquire marketable securities for fiscal 2017 was $47.00K, a 99.80% decline from fiscal 2016.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 3 month as first filed | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 6 month as first filed | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 9 month as first filed | Payments to Acquire Marketable Securities 12 month | Payments to Acquire Marketable Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $66.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $130.70M 10-Q · filed 2026-07-29 | ||||||
| 2026-03-31 | $64.63M 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | $200.26M 10-K · filed 2026-02-26 | |||||||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | $0.00 10-Q · filed 2026-07-29 | ||||||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||||||
| 2017-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $5.00K derived: sum of 2 quarters · filed 2020-02-26 | $19.00K derived: sum of 3 quarters · filed 2020-02-26 | $47.00K 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $20.00K derived: sum of 2 quarters · filed 2018-11-01 | $48.00K 10-Q · filed 2018-11-01 | $2.35M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $42.00K 10-Q · filed 2018-08-02 | $2.35M derived: sum of 3 quarters · filed 2019-03-01 | $19.79M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $28.00K 10-Q · filed 2018-05-08 | $2.33M derived: sum of 2 quarters · filed 2019-03-01 | $19.78M derived: sum of 3 quarters · filed 2019-03-01 | $19.76M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $19.75M derived: sum of 2 quarters · filed 2019-03-01 | $19.73M derived: sum of 3 quarters · filed 2019-03-01 | $23.70M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $17.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $17.43M derived: sum of 2 quarters · filed 2017-11-09 | $21.39M 10-Q · filed 2017-11-09 | $27.47M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-06-30 | -$17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $3.95M 10-Q · filed 2017-08-03 | $10.03M derived: sum of 3 quarters · filed 2018-02-22 | $16.00M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2016-03-31 | $3.97M 10-Q · filed 2017-05-04 | $10.05M derived: sum of 2 quarters · filed 2018-02-22 | $16.02M derived: sum of 3 quarters · filed 2018-02-22 | $20.85M derived: sum of 4 quarters · filed 2018-02-22 | ||||
| 2015-12-31 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $12.05M derived: sum of 2 quarters · filed 2018-02-22 | $16.88M derived: sum of 3 quarters · filed 2018-02-22 | $20.17M 10-K · filed 2018-02-22 | ||||
| 2015-09-30 | $5.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $10.80M derived: sum of 2 quarters · filed 2016-11-03 | $14.09M 10-Q · filed 2016-11-03 | $17.36M derived: sum of 4 quarters · filed 2017-02-23 | ||||
| 2015-06-30 | $4.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $8.12M 10-Q · filed 2016-08-04 | $8.12M 10-Q · filed 2015-08-06 | $11.39M derived: sum of 3 quarters · filed 2017-02-23 | $16.99M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-31 | $3.29M 10-Q · filed 2016-05-05 | $3.29M 10-Q · filed 2015-05-08 | $6.56M derived: sum of 2 quarters · filed 2017-02-23 | $12.16M derived: sum of 3 quarters · filed 2017-02-23 | $21.82M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2014-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $8.87M derived: sum of 2 quarters · filed 2017-02-23 | $18.54M derived: sum of 3 quarters · filed 2017-02-23 | $27.51M 10-K · filed 2017-02-23 | $27.51M 10-K · filed 2015-03-17 | |||
| 2014-09-30 | $5.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $15.27M derived: sum of 2 quarters · filed 2015-11-05 | $24.24M 10-Q · filed 2015-11-05 | $24.24M 10-Q · filed 2014-11-07 | $42.72M derived: sum of 4 quarters · filed 2016-02-25 | |||
| 2014-06-30 | $9.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $18.64M 10-Q · filed 2015-08-06 | $37.12M derived: sum of 3 quarters · filed 2016-02-25 | $43.03M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $8.97M 10-Q · filed 2015-05-08 | $27.45M derived: sum of 2 quarters · filed 2016-02-25 | $33.36M derived: sum of 3 quarters · filed 2016-02-25 | $40.91M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $18.48M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $24.39M derived: sum of 2 quarters · filed 2016-02-25 | $31.94M derived: sum of 3 quarters · filed 2016-02-25 | $42.48M 10-K · filed 2016-02-25 | $42.48M 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $5.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $13.46M derived: sum of 2 quarters · filed 2014-11-07 | $24.00M 10-Q · filed 2014-11-07 | $26.77M derived: sum of 4 quarters · filed 2015-03-17 | ||||
| 2013-06-30 | $7.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $18.09M 10-Q · filed 2014-08-11 | $20.86M derived: sum of 3 quarters · filed 2015-03-17 | $34.22M derived: sum of 4 quarters · filed 2015-03-17 | ||||
| 2013-03-31 | $10.54M 10-Q · filed 2014-05-09 | $13.31M derived: sum of 2 quarters · filed 2015-03-17 | $26.67M derived: sum of 3 quarters · filed 2015-03-17 | $35.04M derived: sum of 4 quarters · filed 2015-03-17 | ||||
| 2012-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-17 | $16.13M derived: sum of 2 quarters · filed 2015-03-17 | $24.50M derived: sum of 3 quarters · filed 2015-03-17 | $39.11M 10-K · filed 2015-03-17 | ||||
| 2012-09-30 | $13.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $21.73M derived: sum of 2 quarters · filed 2013-11-08 | $36.34M 10-Q · filed 2013-11-08 | $46.66M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-06-30 | $8.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07 | $22.98M 10-Q · filed 2013-08-07 | $33.30M derived: sum of 3 quarters · filed 2014-03-14 | $48.17M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2012-03-31 | $14.61M 10-Q · filed 2013-05-07 | $24.93M derived: sum of 2 quarters · filed 2014-03-14 | $39.81M derived: sum of 3 quarters · filed 2014-03-14 | $64.08M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2011-12-31 | $10.32M derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14 | $25.20M derived: sum of 2 quarters · filed 2014-03-14 | $49.47M 10-K · filed 2014-03-14 | $75.70M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2011-09-30 | $14.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09 | $39.15M 10-Q · filed 2011-11-09 | $65.38M 10-Q · filed 2012-11-08 | $90.07M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2011-06-30 | $24.27M 10-Q · filed 2011-08-05 | $50.50M 10-Q · filed 2012-08-09 | $75.19M derived: sum of 3 quarters · filed 2014-03-14 | $90.66M derived: sum of 4 quarters · filed 2014-03-14 | ||||
| 2011-03-31 | $26.23M 10-Q · filed 2012-05-10 | $50.92M derived: sum of 2 quarters · filed 2014-03-14 | $66.40M derived: sum of 3 quarters · filed 2014-03-14 | $84.33M 10-K · filed 2013-03-15 | ||||
| 2010-12-31 | $24.69M derived: 10-K 9 month − 10-Q 6 month · filed 2014-03-14 | $40.16M derived: sum of 2 quarters · filed 2014-03-14 | $58.10M 10-K · filed 2014-03-14 | |||||
| 2010-09-30 | $15.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-11-09 | $33.41M 10-Q · filed 2011-11-09 | ||||||
| 2010-06-30 | $17.93M 10-Q · filed 2011-08-05 | |||||||
| 2010-03-31 | $47.04M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |